Analysis of real-world follow-up data from Chinese CHD patients revealed that, compared to CHD patients not using any PCSK9 inhibitors, those treated with PCSK9 inhibitors exhibited significantly higher incidences of Memory Impairment (<i>p</i> < 0.0001) and Head Discomfort (<i>p</i> = 0.0027).<h4>Conclusion</h4>Our study highlights that it is essential to recognize the potential risks of adverse neurological reactions, particularly Memory Impairment and Head Discomfort. This evidence concerns the gene PCSK9 and memory impairment.